Expert Review Of Clinical Pharmacology SCIE

国际简称：EXPERT REV CLIN PHAR 参考译名：临床药理学专家评审

主要研究方向：PHARMACOLOGY & PHARMACY 非预警期刊审稿周期：

《临床药理学专家评审》(Expert Review Of Clinical Pharmacology)是一本由Taylor and Francis Ltd.出版的以PHARMACOLOGY & PHARMACY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q2 JCR分区
98 年发文量
3.6 IF影响因子
未开放 是否OA
32 H-index
2008 创刊年份
12 issues/year 出版周期
English 出版语言

Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.

Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.

[ 查看全部 ]

投稿咨询加急咨询

Expert Review Of Clinical Pharmacology期刊信息

ISSN：1751-2433
出版语言：English
是否OA：未开放
E-ISSN：1751-2441
出版地区：ENGLAND
是否预警：否
出版商：Taylor and Francis Ltd.
出版周期：12 issues/year
创刊时间：2008
开源占比：0.1047
Gold OA文章占比：11.24%
OA被引用占比：0.0727...
出版国人文章占比：0.06
出版撤稿占比：0
研究类文章占比：35.71%

Expert Review Of Clinical Pharmacology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

7.3

0.99

0.999

学科类别	分区	排名	百分位
大类：Pharmacology, Toxicology and Pharmaceutics 小类：General Pharmacology, Toxicology and Pharmaceutics	Q1	6 / 80	93%
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Pharmacology (medical)	Q1	49 / 272	82%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Expert Review Of Clinical Pharmacology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	3区	PHARMACOLOGY & PHARMACY 药学	3区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	3区	PHARMACOLOGY & PHARMACY 药学	3区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	2区	PHARMACOLOGY & PHARMACY 药学	2区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	3区	PHARMACOLOGY & PHARMACY 药学	3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	2区	PHARMACOLOGY & PHARMACY 药学	2区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	是	医学	2区	PHARMACOLOGY & PHARMACY 药学	2区

Expert Review Of Clinical Pharmacology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	94 / 354	73.6%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	163 / 354	54.1%

Expert Review Of Clinical Pharmacology历年数据统计

影响因子

中科院分区

Expert Review Of Clinical Pharmacology中国学者发文选摘

1、A model based on machine learning for the prediction of cyclosporin A trough concentration in Chinese allo-HSCT patients
Author: Song, Lin; Huang, Chen-Rong; Pan, Shi-Zheng; Zhu, Jian-Guo; Cheng, Zong-Qi; Yu, Xun; Xue, Ling; Xia, Fan; Zhang, Jin-Yuan; Wu, De-Pei; Miao, Li-Yan

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 1, pp. 83-91. DOI: 10.1080/17512433.2023.2142561
2、Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
Author: Ruan, Zhen; Jiang, Yixuan; Shi, Honghao; Jia, Ruxu; Ung, Carolina Oi Lam; Hu, Hao

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 2, pp. 161-176. DOI: 10.1080/17512433.2023.2174099
3、Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring
Author: Li, Qiu-Yue; van den Anker, John; Wu, Yue-E; Hao, Guo-Xiang; Zhao, Wei

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/17512433.2023.2181161
4、Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials
Author: Sun, Xiaoyu; Xu, Suying; Li, Yiming; Lv, Xuemei; Wei, Minjie; He, Miao

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 3, pp. 245-256. DOI: 10.1080/17512433.2023.2188193
5、Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial
Author: Xu, Zhongnan; Liu, Zhengzhi; Wang, Yanli; Xue, Jinling; Chang, Tianying; Cui, Yingzi; Cheng, Yang; Liu, Guangwen; Wang, Wanhua; Zhou, Yannan; Yu, Shuang; Ren, Qing; Yang, Wei; Qu, Xinyao; Chen, Jiahui; Chen, Xuesong; Deng, Qiaohuan; Yang, Haimiao; Wang, Xiuge

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 4, pp. 363-370. DOI: 10.1080/17512433.2023.2188192
6、A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
Author: Zheng, Zhiwei; Zhu, Gaofeng; Cao, Xueqiong; Cai, Hongfu; Zhu, Huide

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 3, pp. 267-273. DOI: 10.1080/17512433.2023.2188194
7、Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma
Author: Wu, Zhuo; Li, Ziran; Qiu, Xiaoyan; Zhong, Mingkang; Ding, Tianling

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. 16, Issue 4, pp. 371-381. DOI: 10.1080/17512433.2023.2194630
8、Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes
Author: Joynt, Gavin Matthew; Ling, Lowell; Wong, Wai Tat; Lipman, Jeffrey

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/17512433.2023.2194629